Medicare AdvantageDocumentationHigh impact
MA07.055e, Allergy Immunotherapy
Independence Blue Cross·Allergy & Immunology, Internal Medicine, Pediatrics·Medical Policy
Effective date
Oct 20, 2025
We identified it
Jun 19, 2026
Summary
Independence Blue Cross MA07.055e reissued effective 10/20/2025 with clarified immunotherapy phases: the policy now uses 'build-up phase' and 'maintenance phase' terminology instead of 'escalation phase.' Specific dose limits (120 doses in year one, 90 doses annually for maintenance) and 1cc aliquot requirements were removed from the medically necessary criteria but retained in the professional services guidelines section, creating potential billing confusion.
Action Required
By 10/20/2025: (1) Billing team must update internal policy documentation to reflect the deletion of 'escalation phase' language and replace with 'build-up phase' terminology in all claim documentation and prior authorization requests. (2) Clarify with providers that while dose limits (120 units year one, 90 units for maintenance) were deleted from medically necessary criteria, they remain in the professional services guidelines (CPT 95165) and must still be monitored for billing purposes. (3) Remove any internal templates, forms, or system rules that reference '1cc aliquot requirements' as these are no longer part of policy language. (4) Do NOT remove dose tracking from billing workflows—the guidelines section still enforces these limits for CPT 95165 claims. (5) Review any pending or denied claims from the current policy period that may have been rejected based on old 'escalation phase' language and consider resubmission under new terminology. Failure to align documentation with new phase terminology could result in claim denials for minor documentation inconsistencies.